XML 69 R54.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS - Narrative (Details)
$ / shares in Units, shares in Millions, $ in Millions
6 Months Ended 12 Months Ended
May 20, 2020
USD ($)
$ / shares
shares
Jun. 30, 2020
USD ($)
Dec. 31, 2020
segment
Dec. 31, 2019
USD ($)
Business Acquisition [Line Items]        
Number of operating segments | segment     1  
Stock Options        
Business Acquisition [Line Items]        
Vesting period     4 years  
Zyla Life Sciences        
Business Acquisition [Line Items]        
Merger exchange ratio 2.5      
Business transaction costs associated with merger   $ 6.6    
Proforma information adjustment, excluded income from Zyla's January 2019 Reorganization       $ 115.2
Proforma information adjustment, excluded loss from impairment of intangible assets       $ 189.8
Zyla Life Sciences | The 2019 Zyla Plan        
Business Acquisition [Line Items]        
Issued (in shares) | shares 5.0      
Issued, average fair market value, per share (in dollars per share) | $ / shares $ 0.62      
Issued, value recognized as merger consideration $ 0.4      
Zyla Life Sciences | Iroko | Warrant Agreements        
Business Acquisition [Line Items]        
Exercise aggregate ownership percentage maximum threshold 49.00%      
Exercise aggregate ownership percentage term 18 months      
Zyla Life Sciences | Stock Options | The 2019 Zyla Plan        
Business Acquisition [Line Items]        
Term of awards (may not exceed) 10 years      
Vesting period 3 years      
Vesting percentage 33.00%